Our top pick for
Morphic Holding Inc is a biotechnology business based in the US. Morphic Holding shares (MORF) are listed on the NASDAQ and all prices are listed in US Dollars. Morphic Holding employs 96 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$58.09|
|52-week range||$24.94 - $75.95|
|50-day moving average||$61.29|
|200-day moving average||$57.71|
|Wall St. target price||$100.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.87|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.12%|
|1 month (2021-09-24)||-9.81%|
|3 months (2021-07-23)||-3.65%|
|6 months (2021-04-23)||5.35%|
|1 year (2020-10-23)||102.69%|
|2 years (2019-10-24)||318.52%|
|3 years (2018-10-21)||N/A|
|5 years (2016-10-21)||N/A|
|Revenue TTM||$38.8 million|
|Gross profit TTM||$-28,685,000|
|Return on assets TTM||-11.92%|
|Return on equity TTM||-26.57%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
There are currently 1.1 million Morphic Holding shares held short by investors – that's known as Morphic Holding's "short interest". This figure is 10.1% up from 956,620 last month.
There are a few different ways that this level of interest in shorting Morphic Holding shares can be evaluated.
Morphic Holding's "short interest ratio" (SIR) is the quantity of Morphic Holding shares currently shorted divided by the average quantity of Morphic Holding shares traded daily (recently around 174943.35548173). Morphic Holding's SIR currently stands at 6.02. In other words for every 100,000 Morphic Holding shares traded daily on the market, roughly 6020 shares are currently held short.
However Morphic Holding's short interest can also be evaluated against the total number of Morphic Holding shares, or, against the total number of tradable Morphic Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Morphic Holding's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Morphic Holding shares in existence, roughly 30 shares are currently held short) or 0.0488% of the tradable shares (for every 100,000 tradable Morphic Holding shares, roughly 49 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Morphic Holding.
Find out more about how you can short Morphic Holding stock.
We're not expecting Morphic Holding to pay a dividend over the next 12 months.
Over the last 12 months, Morphic Holding's shares have ranged in value from as little as $24.94 up to $75.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Morphic Holding's is 1.2712. This would suggest that Morphic Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Morphic Holding, Inc. , a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß1 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.